Business Context and Reporting Period
Company: Pediatrix Medical Group, Inc. (NYSE: MD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Pediatrix is a leading provider of physician services, specializing in newborn, maternal-fetal, and pediatric subspecialty care. The company operates a national network of approximately 2,295 affiliated physicians across 37 states, primarily staffing hospital-based Neonatal Intensive Care Units (NICUs). In 2024, the company completed a strategic shift by exiting almost all office-based practices (except maternal-fetal medicine) and its primary/urgent care service lines to focus on hospital-based care.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $1.91 billion | $2.01 billion |
| Net Income (Loss) | $165.4 million | ($99.1 million) |
| Diluted EPS | $1.94 | ($1.19) |
| Adjusted EBITDA | $275.6 million | $224.0 million |
| Operating Margin | 10.9% | (3.4)% |
| Cash and Cash Equivalents | $375.2 million | $229.9 million |
| Operating Cash Flow | $274.7 million | $217.3 million |
| Total Indebtedness | $596.9 million | $615.6 million |
| Available Credit Facility | $450.0 million | $450.0 million |
Note: 2024 results were significantly impacted by a $150.6 million non-cash goodwill impairment charge and $64.3 million in transformational and restructuring expenses.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 4.9% to $1.91 billion, primarily due to the exit of office-based practices and primary/urgent care service lines in 2024. However, same-unit revenue increased 6.2% driven by improved collections, higher patient acuity, and favorable payor mix shifts.
- Profitability Turnaround: The company returned to profitability with $165.4 million in net income, reversing a $99.1 million loss in 2024. This improvement was driven by the absence of the 2024 goodwill impairment charge and reduced restructuring costs.
- Expense Reduction: Practice salaries and benefits decreased by $100.0 million (6.9%) due to practice dispositions. Transformational and restructuring expenses dropped to $22.3 million from $64.3 million in the prior year.
- Days Sales Outstanding (DSO): Improved from 47.6 days in 2024 to 42.8 days in 2025, reflecting better cash collection efficiency.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management continues to focus on organic growth within hospital-based units and strategic acquisitions. In 2025, the company acquired one maternal-fetal medicine practice and several neonatology/OB hospitalist practices. The company is transitioning its revenue cycle management from a fully outsourced model to a hybrid model utilizing both corporate personnel and third-party providers.
Capital Allocation: The company repurchased approximately 4.3 million shares of common stock in 2025 for $86.7 million. A new $250 million share repurchase program was authorized in August 2025, with $166.2 million remaining available as of year-end.
Key Risks and Contingencies:
- Regulatory & Reimbursement: Significant exposure to government healthcare programs (Medicaid), which accounted for 24% of net revenue. Risks include potential Medicaid reform (e.g., the "One Big Beautiful Bill Act" signed in July 2025), changes in the No Surprises Act (NSA), and potential reductions in reimbursement rates.
- Revenue Cycle Transition: The shift to a hybrid revenue cycle management model carries execution risk; failure to execute efficiently could impact collections and profitability.
- Professional Liability: The company maintains significant reserves ($273.5 million) for professional liability claims, self-insured through a captive subsidiary. Actual losses could exceed estimates.
- Geographic Concentration: Texas accounted for approximately 32% of net revenue in 2025, creating exposure to state-specific regulatory and economic changes.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 6.2% same-unit revenue growth and the impact of the "hybrid" revenue cycle management transition on future Days Sales Outstanding (DSO).
- Payor Mix Stability: Monitor the 24% reliance on government programs (Medicaid) and the potential financial impact of the "One Big Beautiful Bill Act" and other Medicaid reforms on reimbursement rates.
- Liability Reserves: Review the adequacy of the $273.5 million professional liability reserve, given the inherent uncertainty in actuarial projections for medical malpractice claims.
- Debt Covenants: Confirm continued compliance with the Amended Credit Agreement covenants, specifically the minimum interest coverage ratio and maximum consolidated net leverage ratio.
- Acquisition Integration: Assess the integration progress and financial performance of the 2025 acquisitions (maternal-fetal and neonatology practices) to ensure they meet projected growth targets.